Seres Therapeutics (NASDAQ:MCRB) Share Price Crosses Below 50 Day Moving Average of $0.91

Seres Therapeutics, Inc. (NASDAQ:MCRB)’s share price passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $0.91 and traded as low as $0.61. Seres Therapeutics shares last traded at $0.62, with a volume of 3,849,237 shares.

Wall Street Analyst Weigh In

A number of equities analysts have commented on MCRB shares. Chardan Capital reduced their price objective on Seres Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, March 6th. Oppenheimer dropped their target price on Seres Therapeutics from $9.00 to $5.00 and set an “outperform” rating for the company in a research report on Wednesday, March 6th.

Seres Therapeutics Stock Down 1.4 %

The company has a market cap of $94.73 million, a P/E ratio of -0.70 and a beta of 2.23. The business has a 50-day moving average price of $0.89 and a two-hundred day moving average price of $1.15.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings data on Tuesday, March 5th. The biotechnology company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.08. The company had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.50 million. As a group, sell-side analysts expect that Seres Therapeutics, Inc. will post -1.15 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MCRB. Royal Bank of Canada boosted its position in shares of Seres Therapeutics by 78.8% during the second quarter. Royal Bank of Canada now owns 7,411 shares of the biotechnology company’s stock worth $35,000 after buying an additional 3,267 shares during the period. Coppell Advisory Solutions LLC acquired a new position in shares of Seres Therapeutics during the second quarter worth about $39,000. Bridgefront Capital LLC acquired a new position in shares of Seres Therapeutics during the fourth quarter worth about $58,000. Point72 Middle East FZE acquired a new position in shares of Seres Therapeutics during the fourth quarter worth about $61,000. Finally, Commonwealth Equity Services LLC acquired a new position in shares of Seres Therapeutics during the third quarter worth about $26,000. 59.34% of the stock is owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.